Aclaris Advances in FDA Development Stages: Implications of Major Shareholder Stock Sale
Clinical-stage biotech Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is advancing the development of its dual-target antibody ATI-052, which is currently in early human trials under FDA review. After receiving FDA clearance for the IND in April 2025, the company announced on April 28, 2026, that full topline results from its Phase 1a healthy volunteer study surpassed safety, pharmacokinetic and pharmacodynamic targets. The drug was well tolerated at doses up to 720 mg and demonstrated an approximately 45-day half-life, suggesting the potential for once-per-quarter dosing. A Phase 1b proof-of-concept trial in atopic dermatitis and asthma patients is underway in the US, with topline 1b data expected in H2 2026 and a Phase 2b trial targeted for Q4 2026, pending FDA approval.
Aclaris Therapeutics, headquartered in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company developing antibody and oral small-molecule therapies for immune and inflammatory diseases. Its lead pipeline comprises ATI-052, a bispecific antibody targeting TSLP and the IL-4 receptor, and ATI-2138, a selective ITK/JAK3 inhibitor, aimed at high-unmet-need markets in immunological and dermatological conditions such as atopic dermatitis, asthma and lichen planus. Listed on Nasdaq, Aclaris remains in the clinical development stage and has not yet obtained any FDA approvals for commercial products.
On the equity front, a major shareholder has disclosed a sale. In a Form 4 filing with the US Securities and Exchange Commission on April 27 (US time), BML Investment Partners, managed by Braden M. Leonard, reported selling 300,000 Aclaris common shares on April 23 at an average price of $4.53 per share, realizing proceeds of approximately $1.359 million. Following this transaction, the investor’s indirect holding decreased to 13.95 million shares but remains substantial, indicating continued long-term exposure to the clinical readouts of ATI-052 and ATI-2138 and future FDA regulatory milestones.